Application of tumor treating fields for newly diagnosed glioblastoma

understanding of nationwide practice patterns

Shearwood McClelland, Oluwadamilola Sosanya, Timur Mitin, Catherine Degnin, Yiyi Chen, Albert Attia, John H. Suh, Jerry Jaboin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Tumor treating fields (TTF) harness magnetic fields to induce apoptosis in targeted regions. A 2015 landmark randomized phase III trial of newly diagnosed glioblastoma (GBM) patients demonstrated TTF + temozolomide to be superior to temozolomide alone. Given these results, we sought to assess practice patterns of providers in TTF utilization for GBM. Methods: A survey was administered to practices in the United States self-identifying as specializing in radiation oncology, medical oncology, neuro-oncology, neurosurgery, and/or neurology. Responses were collected anonymously; analysis was performed using Fisher’s exact test. Results: A total of 106 providers responded; a minority (36%) were in private practice. Regarding case volume, 82% treated at least six high-grade gliomas/year. The provider most commonly certified to offer TTF therapy to GBM patients was the neuro-oncologist (40%), followed by the radiation oncologist (34%); 31% reported no TTF-certified physician in their practice. TTF users were more likely to have high volume, and be aware of TTF inclusion in National Comprehensive Cancer Network (NCCN) guidelines (p < 0.05). Conclusions: More than 80% of TTF for GBM in the United States is performed by groups who treat at least six high-grade gliomas per year; unfortunately more than 30% were in practices bereft of anyone certified to offer TTF therapy. These results indicate that there remains fertile soil for TTF therapy nationwide to be introduced into practices for GBM treatment. Providers seeking to refer newly diagnosed GBM patients for TTF should seek out practices with TTF user-associated characteristics to ensure optimal access for their patients.

Original languageEnglish (US)
Pages (from-to)1-4
Number of pages4
JournalJournal of Neuro-Oncology
DOIs
StateAccepted/In press - Jul 9 2018

Fingerprint

Glioblastoma
Neoplasms
temozolomide
Glioma
Radiation Oncology
Medical Oncology
Private Practice
Neurosurgery
Magnetic Fields
Therapeutics
Neurology
Soil
Guidelines
Apoptosis

Keywords

  • Glioblastoma
  • National comprehensive cancer network guidelines
  • Neuro-oncology
  • Radiation oncology
  • Tumor treating fields

ASJC Scopus subject areas

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Application of tumor treating fields for newly diagnosed glioblastoma : understanding of nationwide practice patterns. / McClelland, Shearwood; Sosanya, Oluwadamilola; Mitin, Timur; Degnin, Catherine; Chen, Yiyi; Attia, Albert; Suh, John H.; Jaboin, Jerry.

In: Journal of Neuro-Oncology, 09.07.2018, p. 1-4.

Research output: Contribution to journalArticle

McClelland, Shearwood ; Sosanya, Oluwadamilola ; Mitin, Timur ; Degnin, Catherine ; Chen, Yiyi ; Attia, Albert ; Suh, John H. ; Jaboin, Jerry. / Application of tumor treating fields for newly diagnosed glioblastoma : understanding of nationwide practice patterns. In: Journal of Neuro-Oncology. 2018 ; pp. 1-4.
@article{e4079a072f3e4f209dbeacd51d36154c,
title = "Application of tumor treating fields for newly diagnosed glioblastoma: understanding of nationwide practice patterns",
abstract = "Background: Tumor treating fields (TTF) harness magnetic fields to induce apoptosis in targeted regions. A 2015 landmark randomized phase III trial of newly diagnosed glioblastoma (GBM) patients demonstrated TTF + temozolomide to be superior to temozolomide alone. Given these results, we sought to assess practice patterns of providers in TTF utilization for GBM. Methods: A survey was administered to practices in the United States self-identifying as specializing in radiation oncology, medical oncology, neuro-oncology, neurosurgery, and/or neurology. Responses were collected anonymously; analysis was performed using Fisher’s exact test. Results: A total of 106 providers responded; a minority (36{\%}) were in private practice. Regarding case volume, 82{\%} treated at least six high-grade gliomas/year. The provider most commonly certified to offer TTF therapy to GBM patients was the neuro-oncologist (40{\%}), followed by the radiation oncologist (34{\%}); 31{\%} reported no TTF-certified physician in their practice. TTF users were more likely to have high volume, and be aware of TTF inclusion in National Comprehensive Cancer Network (NCCN) guidelines (p < 0.05). Conclusions: More than 80{\%} of TTF for GBM in the United States is performed by groups who treat at least six high-grade gliomas per year; unfortunately more than 30{\%} were in practices bereft of anyone certified to offer TTF therapy. These results indicate that there remains fertile soil for TTF therapy nationwide to be introduced into practices for GBM treatment. Providers seeking to refer newly diagnosed GBM patients for TTF should seek out practices with TTF user-associated characteristics to ensure optimal access for their patients.",
keywords = "Glioblastoma, National comprehensive cancer network guidelines, Neuro-oncology, Radiation oncology, Tumor treating fields",
author = "Shearwood McClelland and Oluwadamilola Sosanya and Timur Mitin and Catherine Degnin and Yiyi Chen and Albert Attia and Suh, {John H.} and Jerry Jaboin",
year = "2018",
month = "7",
day = "9",
doi = "10.1007/s11060-018-2945-y",
language = "English (US)",
pages = "1--4",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",

}

TY - JOUR

T1 - Application of tumor treating fields for newly diagnosed glioblastoma

T2 - understanding of nationwide practice patterns

AU - McClelland, Shearwood

AU - Sosanya, Oluwadamilola

AU - Mitin, Timur

AU - Degnin, Catherine

AU - Chen, Yiyi

AU - Attia, Albert

AU - Suh, John H.

AU - Jaboin, Jerry

PY - 2018/7/9

Y1 - 2018/7/9

N2 - Background: Tumor treating fields (TTF) harness magnetic fields to induce apoptosis in targeted regions. A 2015 landmark randomized phase III trial of newly diagnosed glioblastoma (GBM) patients demonstrated TTF + temozolomide to be superior to temozolomide alone. Given these results, we sought to assess practice patterns of providers in TTF utilization for GBM. Methods: A survey was administered to practices in the United States self-identifying as specializing in radiation oncology, medical oncology, neuro-oncology, neurosurgery, and/or neurology. Responses were collected anonymously; analysis was performed using Fisher’s exact test. Results: A total of 106 providers responded; a minority (36%) were in private practice. Regarding case volume, 82% treated at least six high-grade gliomas/year. The provider most commonly certified to offer TTF therapy to GBM patients was the neuro-oncologist (40%), followed by the radiation oncologist (34%); 31% reported no TTF-certified physician in their practice. TTF users were more likely to have high volume, and be aware of TTF inclusion in National Comprehensive Cancer Network (NCCN) guidelines (p < 0.05). Conclusions: More than 80% of TTF for GBM in the United States is performed by groups who treat at least six high-grade gliomas per year; unfortunately more than 30% were in practices bereft of anyone certified to offer TTF therapy. These results indicate that there remains fertile soil for TTF therapy nationwide to be introduced into practices for GBM treatment. Providers seeking to refer newly diagnosed GBM patients for TTF should seek out practices with TTF user-associated characteristics to ensure optimal access for their patients.

AB - Background: Tumor treating fields (TTF) harness magnetic fields to induce apoptosis in targeted regions. A 2015 landmark randomized phase III trial of newly diagnosed glioblastoma (GBM) patients demonstrated TTF + temozolomide to be superior to temozolomide alone. Given these results, we sought to assess practice patterns of providers in TTF utilization for GBM. Methods: A survey was administered to practices in the United States self-identifying as specializing in radiation oncology, medical oncology, neuro-oncology, neurosurgery, and/or neurology. Responses were collected anonymously; analysis was performed using Fisher’s exact test. Results: A total of 106 providers responded; a minority (36%) were in private practice. Regarding case volume, 82% treated at least six high-grade gliomas/year. The provider most commonly certified to offer TTF therapy to GBM patients was the neuro-oncologist (40%), followed by the radiation oncologist (34%); 31% reported no TTF-certified physician in their practice. TTF users were more likely to have high volume, and be aware of TTF inclusion in National Comprehensive Cancer Network (NCCN) guidelines (p < 0.05). Conclusions: More than 80% of TTF for GBM in the United States is performed by groups who treat at least six high-grade gliomas per year; unfortunately more than 30% were in practices bereft of anyone certified to offer TTF therapy. These results indicate that there remains fertile soil for TTF therapy nationwide to be introduced into practices for GBM treatment. Providers seeking to refer newly diagnosed GBM patients for TTF should seek out practices with TTF user-associated characteristics to ensure optimal access for their patients.

KW - Glioblastoma

KW - National comprehensive cancer network guidelines

KW - Neuro-oncology

KW - Radiation oncology

KW - Tumor treating fields

UR - http://www.scopus.com/inward/record.url?scp=85049641122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049641122&partnerID=8YFLogxK

U2 - 10.1007/s11060-018-2945-y

DO - 10.1007/s11060-018-2945-y

M3 - Article

SP - 1

EP - 4

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

ER -